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Abstract
The integrin αvβ3, whose αv subunit is encoded by the ITGAV
gene, plays a key role in angiogenesis. Hyperangiogenesis is
involved in rheumatoid arthritis (RA) and the ITGAV  gene is
located in 2q31, one of the suggested RA susceptibility loci.
Our aim was to test the ITGAV gene for association and linkage
to RA in a family-based study from the European Caucasian
population.
Two single nucleotide polymorphisms were genotyped by PCR-
restriction fragment length polymorphism in 100 French
Caucasian RA trio families (one RA patient and both parents),
100 other French families and 265 European families available
for replication. The genetic analyses for association and linkage
were performed using the comparison of allelic frequencies
(affected family-based controls), the transmission disequilibrium
test, and the genotype relative risk.
We observed a significant RA association for the C allele of
rs3738919 in the first sample (affected family-based controls,
RA index cases 66.5% versus controls 56.7%; P = 0.04). The
second sample showed the same trend, and the third sample
again showed a significant RA association. When all sets were
combined, the association was confirmed (affected family-
based controls, RA index cases 64.6% versus controls 58.1%;
P = 0.005). The rs3738919-C allele was also linked to RA
(transmission disequilibrium test, 56.5% versus50% of
transmission; P = 0.009) and the C-allele-containing genotype
was more frequent in RA index cases than in controls (RA index
cases 372 versus controls 339; P = 0.002, odds ratio = 1.94,
95% confidence interval = 1.3–2.9).
The rs3738919-C allele of the ITGAV gene is associated with
RA in the European Caucasian population, suggesting ITGAV
as a new minor RA susceptibility gene.
AFBAC = affected family-based controls; bp = base pair; GRR = genotype relative risk; PCR = polymerase chain reaction; RA = rheumatoid arthritis; 
SNP = single nucleotide polymorphism; TDT = transmission disequilibrium test.Arthritis Research & Therapy    Vol 9 No 4    Jacq et al.
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Introduction
Rheumatoid arthritis (RA) is the most common human sys-
temic autoimmune disease (0.8% prevalence in the European
Caucasian population), affecting women preferentially [1]. The
disease is characterized by a chronic inflammation of the syn-
ovial tissues leading to the formation of the rheumatoid pan-
nus, which erodes adjacent cartilage and bone, causing
subsequent joint destruction. One hallmark of the pannus is
hyperangiogenesis [2].
Previous studies have indicated that the risk of developing the
disease in siblings of affected individuals is 2–17 times higher
than in the general population, suggesting the importance of
genetic factors [1]. Two RA genes have so far been estab-
lished and confirmed using familial material, HLA-DRB1 and
PTPN22 [3,4], but they account only for a part of the RA
genetic component. The dense genome scan realized in our
laboratory suggested 19 non-HLA regions in the French Cau-
casian population [5] and one of these, 2q31, contains the
ITGAV gene (alias CD51, αv), which encodes the αv subunit
of the integrin family. This family is composed of at least 24
heterodimeric combinations of 18 α subunits and nine β sub-
units. These transmembranous receptors are expressed at the
surface of numerous cells (endothelial cells, macrophages,
monocytes, osteoclasts, platelets) and recognize the RGD
sequence (Arg–Gly–Asp) of many ligands (such as vitronec-
tin, fibronectin, osteopontin, sialoprotein, thrombospondin,
fibrinogen, von Willebrand factor, tenascin, agrin, matrix metal-
loproteinases, and prothrombin) [6]. The integrins are involved
in several functions including adhesion of activated endothelial
cells with the extracellular matrix, proliferation, migration, and
differentiation signals of vascular cells [6].
The αvβ3 integrin is well documented to play a key role in ang-
iogenesis, and the ITGAV knockout animal model is lethal in
utero for 80% with a presence of large vascular anomalies
[7,8].
Angiogenesis also plays a key role in RA when the synovial
membrane becomes hyperplasic and destroys the cartilage.
We can observe an excess of blood cells (macrophages, T
lymphocytes) in the synovial membrane and fluid, and some
αvβ3 ligands (that is, fibrinogen or osteopontin) are abundant
in the RA synovial fluid [7]. Moreover, some proangiogenic
mediators (that is, vascular endothelial growth factor) are over-
expressed in RA synovial membrane and serum [9,10].
In addition, several αvβ3 antagonists and angiogenesis inhibi-
tors have been successfully tested on RA animal models [11-
14]. The αvβ3 integrin could therefore become a new thera-
peutic target in RA, and some clinical studies have already
begun [15].
Our aim was to use RA familial material to test two intronic
ITGAV single nucleotide polymorphisms (SNPs) for RA asso-
ciation and linkage in the European Caucasian population.
Materials and methods
All subjects provided informed consent, and the ethics com-
mittee of Hôpital Bicêtre (Kremlin-Bicêtre, Assistance Pub-
lique-Hôpitaux de Paris, France) approved the study. RA
families were recruited through a national media campaign fol-
lowed by selection of individuals who fulfilled the 1987 Amer-
ican College of Rheumatology criteria for RA according to the
physicians in charge of the patients [16]. A rheumatologist uni-
versity fellow reviewed all clinical data.
Sample 1
Sample 1 (Table 1) constituted the DNA from 100 French
Caucasian unrelated trio families (one RA patient and both
parents) with the four grandparents of French Caucasian ori-
gin. Among these 100 RA patients, 87 were women; their
mean age at disease onset was 32 years. In total, 81 patients
were rheumatoid factor positive, 78 patients carried at least
one  HLA-DRB1  'shared epitope' susceptibility allele
(DRB1*0101, DRB1*0102, DRB1*0401, DRB1*0404,
DRB1*0405, DRB1*0408, DRB1*1001) [17] and 90 patients
presented erosion.
Table 1
Characteristics of rheumatoid arthritis (RA) index cases from the investigated samples
Sample 1 (n = 100) Sample 2 (n = 100) Sample 3 (n = 265)
Females (%) 87 90 86
Mean age of disease onset (years) (±standard deviation) 32 (±10) 31 (±6) 30 (±9)
Mean disease duration (years) (±standard deviation) 18 (±7) 16 (±8) 8 (±7)
RA patients with bone erosions (%) 90 79 72
RA patients seropositive for rheumatoid factor (%) 81 76 73
RA patients carrying at least one HLA-DRB1 shared epitope allele (%) 78 80 Not available
n, number of cases.Available online http://arthritis-research.com/content/9/4/R63
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Sample 2
Sample 2 (Table 1) was made up of the DNA from another 100
French Caucasian unrelated trio families with the same char-
acteristics as sample 1. Among these 100 RA patients, 90
patients were women; their mean age at disease onset was 31
years. In all, 76 patients were rheumatoid factor positive, 80
patients carried at least one HLA-DRB1 shared epitope and
79 patients had an erosive disease.
Sample 3
Sample 3 (Table 1) contained the DNA from 265 European
Caucasian unrelated trio families with the same characteristics
as sample 1, except for a shorter mean disease duration and a
different ethnic origin (Caucasian families from France, Italy,
Portugal, Spain, Belgium, and The Netherlands).
Genotyping
DNA was isolated and purified from whole blood according to
standard protocols [18]. Two intronic SNPs were selected at
the 5' and 3' ends of the gene with a minor allele frequency
>25% for European population databases. Moreover the pres-
ence of a restriction site for one of the alleles was required
(SNP1, rs3768777; SNP2, rs3738919 [19,20]). Genotyping
was performed by the PCR followed by restriction fragment
length polymorphism method [21].
The designed primers were: sense, 5'-AAGTTGCCAACGT-
TCCGCGTTGCA-3' and antisense, 5'-GTAGTAGAAGAT-
GGTCCTATCCACG-3' for SNP1; and sense, 5'-
ATTTCCAGGTGGAACTTCTTTTGGA-3' and antisense, 5'-
TCACAATTCAGATTTTTGCCACTGG-3' for SNP2.
PCR amplification of SNP1 and SNP2 was performed on each
sample in a 25 μl reaction volume consisting of 10 U PCR
buffer (Perkin Elmer, Boston, MA, USA), 1.25 mM each dNTP,
1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems,
Foster City, CA, USA), 3 mM MgCl2, 0.0125 nM of the two
primers and 50 ng genomic DNA, diluted to the final volume
with H2O on an Eppendorf thermocycler using a hot start pro-
cedure. The PCR program was carried out using a first dena-
turation cycle of 94°C for 10 minutes followed by 37 cycles of
denaturation at 94°C for 40 seconds, with an annealing tem-
perature at 67°C for 30 seconds followed by an elongation
step at 72°C for 1 minute. One final cycle of the extension was
performed at 72°C for 2 minutes.
For SNP1, a 341-bp amplified fragment was digested with
NlaIII, generating two fragments when the restriction site was
present (A allele). For SNP2, the resulting 501-bp fragment
was digested with AluI, generating three fragments for the C
allele (126 bp, 161 bp and 214 bp), and two fragments for the
A allele (permanent restriction site allowing one to validate the
restriction protocol; 161 bp and 340 bp). Genotypes were
assessed blindly by two independent investigators (LJ and
CP). CEPH controls (1347-02 and 884-15) and 40 patients
chosen at random were genotyped for quality control. All gen-
otype data will be available online [22].
Power calculation
Using the European population minor allele frequency of 29%
and 35% for SNP1 and SNP2, respectively, a sample size of
100 patients and 100 controls, and the arc sinus transforma-
tion method described by Garnier and colleagues [23], we
had 80% power to detect an association (P < 0.05) if the dif-
ference in allelic frequencies between patients and controls
was at least 11% for SNP1 and 12.2% for SNP2.
Statistical analysis
Prior to association tests, we checked the Hardy–Weinberg
equilibrium in 'virtual controls' (constituted by parental untrans-
mitted alleles to RA index cases).
The association and linkage between each polymorphism and
RA was examined by three different methods: the affected
family-based controls (AFBAC) method was used to compare
transmitted and untransmitted allelic frequencies across all
families, the transmission disequilibrium test (TDT) was used
to detect linkage through preferential transmission of one
allele to the affected subjects, and the genotype relative risk
(GRR) test was used to compare the genotypic distribution in
patients and controls [24-26]. The significance of the P value
was assessed at 5%, leading to replication tests in sample 2
and, in the case of relevant results, in the larger sample 3.
Results
Hardy–Weinberg equilibrium
Hardy–Weinberg equilibrium in the virtual controls was
respected for SNP1 and SNP2 in sample 1 and in the replica-
tion samples (data not shown).
Test for association and linkage in sample 1
We observed neither significant association nor linkage
between SNP1 and RA in sample 1. For SNP2, we observed
a significant association for the C allele and a strong trend for
a RA linkage (AFBAC, RA index cases 66.5% versus controls
56.7%, P = 0.04; TDT, 59.7% of transmission versus 50%, P
= 0.06) (Table 2). The GRR test showed a significant increase
of the C/C genotype and an excess of C-allele-containing gen-
otypes in patients (Table 3).
The linkage disequilibrium test showed a weak linkage dise-
quilibrium between SNP1 and SNP2 (D' = 0.33), and were
thus considered independent. The results of the haplotypic
TDT analysis showed a significant undertransmission of the
SNP1/SNP2 GA haplotype (21 versus 37, P = 0.03), and a
trend for an overtransmission of the two haplotypes containing
the C allele of SNP2 (data not shown).Arthritis Research & Therapy    Vol 9 No 4    Jacq et al.
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When stratifying the sample for the families with the index pre-
senting at least one PTPN22-620W allele or the HLA-DRB1
allele shared epitope status, no correlation with the ITGAV
genotypes could be observed (data not shown).
Test for association and linkage in sample 2
The significant association observed for SNP2 in sample 1 led
to a replication test in a second set of 100 French Caucasian
Trio families (sample 2) on the hypothesis of an association of
the C allele.
In this sample, we observed a trend for association and linkage
of the C allele with RA (AFBAC, RA index cases 63.1% versus
controls 59.6%, P = 0.4; TDT, 52.6% of transmission, P =
0.6) (Table 4). The GRR test showed a trend for an excess of
the C-allele-containing genotype in RA index cases compared
with controls (90 RA index cases versus 79 controls, P =
0.09) but not for the C/C genotype (Table 5).
The combination of the two samples, authorized by the
absence of any significant clinical difference between them,
showed a marginally significant association of the C allele
(AFBAC, RA index cases 64.8% versus controls 58.2%, P =
0.05; TDT, 56.1% of transmission, P = 0.09) and a significant
excess of the C-allele-containing genotype in RA index cases
compared with controls (173 RA index cases versus 157 con-
trols, P = 0.02).
Test for association and linkage in sample 3
The trend for association of the C allele observed in sample 2
was in the same direction as the significant association
observed in sample 1, without reaching statistical significance
– notably due to a lack of power (the power to detect a signif-
icant association in sample 2, based on the allelic frequencies
in sample 1, with P < 0.05, was only 51%). A larger replication
test (265 families, sample 3) was therefore conducted on the
hypothesis of an association of the C allele and of the C-allele-
containing genotype.
Table 2
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism (SNP)1 and SNP2 
in sample 1 of rheumatoid arthritis trio families
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid 
arthritis cases
Controls P Transmission (%) nP
SNP1
A 0.360 0.320 0.39 54.4 90 0.39
G 0.640 0.680
SNP2
C 0.665 0.567 0.04 59.7 92 0.06
A 0.335 0.433
n, number of heterozygote parents.
Table 3
Genotype relative risk analysis for single nucleotide polymorphism (SNP)1 and SNP2 in sample 1 of rheumatoid arthritis trio 
families
Genotype Rheumatoid arthritis cases Controls P
SNP1
A/A 16 7 0.1 (global)
A/G 40 50
G/G 44 43
SNP2
C/C 45 32 0.03 (C/C versus C/A + A/A)
C/A 38 46 0.36 (C/C + C/A versus A/A)
A/A 13 18Available online http://arthritis-research.com/content/9/4/R63
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We observed a significant RA association and linkage for the
C allele (AFBAC, RA index cases 64.4% versus controls
57.8%, P = 0.03; TDT, 57% of transmission versus 50%, P =
0.04) (Table 6). This increase was supported by a significant
increase of the C-allele-containing genotype in patients (199
RA index cases versus 182 controls, P = 0.02) (Table 7).
Test for association and linkage in the combined 
samples 1 + 2 + 3
The combination of the three samples, authorized by the
absence of a significant clinical difference between them, con-
firmed association and linkage for the C allele (AFBAC, 64.6%
versus 58.1%, P = 0.005; TDT, 56.5% of transmission, P =
0.009) (Table 8). The GRR test showed an excess of the C-
allele-containing genotype in patients (372 RA index cases
versus 339 controls, P = 0.002, odds ratio = 1.94, 95% con-
fidence interval = 1.3–2.9) (Table 9).
Discussion
We studied the ITGAV gene, a good RA candidate gene for
its function implicated in angiogenesis, and its chromosomal
location (in one of the 19 suggested non-HLA  loci of our
dense genome scan) [5]. We observed a significant RA asso-
ciation for the C allele of rs3738919 in a first sample of French
Caucasian families, the same trend in replication sample 2,
and again a significant association in replication sample 3
(European Caucasian families). Finally, significant RA associa-
tion and linkage were observed when all sets were combined.
The association and linkage evidences provided by the
present study remain nevertheless statistically modest, sug-
gesting at most a minor RA susceptibility marker. Further stud-
ies in independent samples will be needed to definitively
establish association and linkage of the ITGAV rs3738919-C
allele to RA. For the observed allelic frequencies of 64.6% in
patients versus 58.1% in controls, a sample size of 350 fami-
lies would be required to obtain, with 80% power (P < 0.05),
an independent replication of the association evidence
reported here.
Once this association had been replicated, resequencing
would be necessary to identify exonic and promoter SNPs to
refine the associated haplotype.
In the same way, the chromosome 2 linkage suggestion
observed in the genome scan of our laboratory could not be
totally explained by the findings of the ITGAV linkage; hence,
with the overtransmission observed in the TDT, the allele shar-
ing expected for the affected sib-pair siblings would be about
53% and would necessitate thousands of sibling pairs to be
revealed. Other RA genes in this chromosomal location and/or
epistatic effects could be expected to be stronger RA factors
that remain to be discovered.
Since the association evidence is modest, no genetic testing
would be clinically indicated. Instead, the clinical relevance of
the finding is likely to come through better understanding of
the RA pathophysiology and may lead to new therapeutic
targets.
Contrary to the result of the GRR test in sample 1, which sug-
gested a recessive effect of the ITGAV rs3738919-C allele,
the result of the larger combined sample is more in favour of a
dominant effect of this marker. This difference could be
explained by the relatively small size of the first sample.
Table 4
Affected family-based control and transmission disequilibrium test analyses for single nucleotide polymorphism 2 in sample 2 of 
rheumatoid arthritis trio families
Allele Affected family-based controls Transmission disequilibrium test
Rheumatoid 
arthritis cases
Controls P Transmission (%) nP
C 0.631 0.596 0.4 52.6 95 0.6
n, number of heterozygote parents.
Table 5
Genotype relative risk analysis for single nucleotide polymorphism 2 in sample 2 of rheumatoid arthritis trio families
Genotype Rheumatoid arthritis cases Controls P
C/C 33 39 0.4 (C/C versus C/A + A/A)
C/A 57 40 0.09 (C/C + C/A versus A/A)
A/A 8 19Arthritis Research & Therapy    Vol 9 No 4    Jacq et al.
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Finally, regarding the key function of angiogenesis in others
diseases, and in particular in cancers, it would be interesting
to test the ITGAV rs3738919-C allele in these phenotypes.
Conclusion
The present study showed a significant association and link-
age for the rs3738919-C allele of the ITGAV gene with RA in
the European Caucasian population, suggesting ITGAV as a
new minor RA susceptibility gene in this population.
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